Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest NewLink Genetics Corporation Stories

2013-06-03 08:27:31

Median Overall Survival was More than Double in Patients with Elevated Levels of Anti-Mesothelin Antibodies Compared to Those without Elevated Levels; AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from a Phase 2 clinical study with its drug candidate algenpantucel-L.The open-label, two-armed, multi-center study evaluated algenpantucel-L plus...

2013-06-03 08:27:28

Data Demonstrate Evidence of Indoximod's Safety and Anti-Tumor Activity When Used in Combination with Other Anti-Cancer Agents in Metastatic Solid Tumors AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway. Indoximod was tested...

2013-06-01 08:21:31

Data Demonstrate Favorable Outcomes for Tergenpumatucel-L as a Single Agent and Potential to Enhance Salvage Chemotherapy Efficacy in Previously Treated Patients AMES, Iowa, June 1, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from a Phase 2 clinical study with tergenpumatucel-L. The study evaluated the safety and activity of tergenpumatucel-L in 28 previously...

2013-05-29 08:30:58

AMES, Iowa, May 29, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Jefferies 2013 Healthcare Conference in New York on Wednesday, June 5, 2013 at 1:00 p.m. ET. Interested parties may...

2013-04-25 08:34:03

AMES, Iowa, April 25, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that Nicholas N. Vahanian, M.D., NewLink's Chief Medical Officer, is scheduled to present at the Needham and Company 12th Annual Healthcare Conference in New York on Tuesday, April 30, 2013 at 12:50 p.m. ET. About NewLink Genetics Corporation NewLink...

2013-04-08 08:29:46

Results Support Further Evaluation of NLG919 for the treatment of Immunosupression Associated with Cancers AMES, Iowa, April 8, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American...

2013-04-04 08:28:15

AMES, Iowa, April 4, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics. The company today announced that preclinical data on one of its IDO pathway inhibitors, NLG919, will be presented at the 2013 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 6-10 in Washington, DC. The poster presentation will describe the benefits of...

2013-02-25 12:25:36

AMES, Iowa, Feb. 25, 2013 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that its Fourth Quarter and fiscal year ended December 31, 2012 financial results will be released before the market opens on Thursday, February 28, 2013. The NewLink management team will host a conference call discussing the company's financial results and recent corporate developments on Thursday, February 28, 2013, at 10:00am EST. The call can be accessed by dialing 1-(877) 363-5052...

2013-02-04 12:25:24

AMES, Iowa, Feb. 4, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently announced public offering of 4,000,000 shares of common stock have exercised in full their option to purchase an additional 600,000 shares. The offering closed today. All shares were sold by NewLink. Aggregate net proceeds to the company were...

2013-01-29 16:24:40

AMES, Iowa, Jan. 29, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The Company...